Amgen Posts Medical Education and Foundation Grants and Donations

AmgenAmgen (NASDAQ: AMGN) posted to the company's Web site grants and donations made by the Amgen Medical Education department (AmgenMED) and the Amgen Foundation. The posting is the latest element of Clearly Amgen, a section of the Company's Web site designed to provide clear and easy access to Amgen's policies and practices. Grants, donations and charitable contributions will be updated quarterly along with a brief description of each program or project.

The company launched Clearly Amgen in December 2007. The site features easy navigation to summaries of policies on ethical research, clinical data disclosure, responsible marketing, and as other topics of interest to Amgen stakeholders (www.amgen.com/about/amgen_policies).

The AmgenMED and Amgen Foundation grant and donation lists, as well as the guidelines governing these grants and donations, are the newest addition to the Clearly Amgen section of the Company's Web site. The lists are also accessible in the corporate giving section of the Web site - www.amgen.com/citizenship/donation_list_overview.htlm.

AmgenMED makes donations to support independent medical education, ancillary support for healthcare professionals in training, clinical practice guidelines support, fellowships, fundraising or charitable events, junior faculty awards, patient and public education programs, pharmacy residency and professional medical society support. The Amgen Foundation gives grants to non-profit organizations that work to advance science education, improve quality of care and access for patients, and create sound communities where Amgen staff live and work.

"We help fulfill our mission of serving patients when we provide support for medical education, patient organizations, scientific institutions and the community," said David Beier, Amgen's senior vice president of Global Government and Corporate Affairs. "This support advances science and helps patients and healthcare professionals in many ways, from training science teachers to educating healthcare providers about disease awareness, prevention and treatment options."

In the first quarter of 2008, the Amgen Foundation provided more than $300,000 in grants. The Foundation also contributed more than $980,000 in matching staff gifts to nearly 1,000 organizations.

AmgenMED made more than $11 million in donations and grants to 177 organizations that advance medicine and healthcare, promote healthcare professional education, educate the public on disease and medical conditions and support charitable purposes that benefit patients.

In one example of corporate giving, in the first quarter of 2008 AmgenMED contributed $100,000 to the Prevent Cancer Foundation for National Colorectal Cancer Awareness Month initiatives and the 2008 Check Your Insides Out Exhibit Tour.

"Support from Amgen has enabled the Prevent Cancer Foundation to reach millions of Americans with the life saving message that colorectal cancer is 'Preventable, Treatable and Beatable'," said Carolyn R. Aldige, president and founder of the Prevent Cancer Foundation.

Another example of a contribution by AmgenMED during the first quarter is $60,000 to the American Kidney Fund's "Kid"ney Kids Art & Calendar Contest." Reaching nearly 100,000 people across the country, the calendar is a creative educational tool that includes health tips and information on chronic kidney disease prevention, risk factors and organ and tissue donation options. The calendar, now in its 13th year, provides the opportunity for pediatric kidney patients to express themselves through artwork and submit it to a nationwide contest. Winners receive a trip to Washington, D.C. and are honored with an awards dinner.

"Thanks to the generosity of Amgen, for these children it is not just a trip but a life changing experience--for many it is the first time they learn that they are not the only child with this disease," said Elizabeth Gunthert, director of corporate and foundation giving at the American Kidney Fund. "Because of our program, the children receive an opportunity to develop lasting friendships with other pediatric kidney patients."

Grants and donations provided by AmgenMED and the Amgen Foundation are compliant with federal and state laws, as well as industry and academic codes and guidelines that govern such activities. In addition, Amgen applies strict standards to all of our interactions with health care professionals and other customers.

For more information about donations and grants made by AmgenMED and the Amgen Foundation or to learn how to apply, visit www.amgen.com/citizenship/overview.html.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

About the Amgen Foundation
The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education, improve patient access to quality care, and strengthen the communities where Amgen staff members live and work. Since 1991, the foundation has made nearly $110 million in grants to local, regional, and national nonprofit organizations that impact society in inspiring and innovative ways. It has also supported disaster relief efforts both domestically and internationally.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...